军事医学2025，Vol.49Issue(9)：687-693,7.DOI:10.7644/j.issn.1674-9960.2025.09.007
超声特征联合免疫组化建立乳腺癌新辅助化疗疗效的预测模型及价值分析
Predictive modeling of efficacy of neoadjuvant chemotherapy for breast cancer using ultrasound and immunohistochemistry
李兆云 1庞月 2陈翠京 1毛京宁 1杜芮 3汉婉晴 4田红丽 1皋月娟 1白玲1
作者信息
- 1. 解放军总医院第五医学中心超声诊断科,北京 100071
- 2. 济南市第五人民医院超声诊断科,济南 250022
- 3. 国家电网公司北京电力医院超声诊断科,北京 100073
- 4. 南京市高淳区人民医院超声诊断科,南京 211303
- 折叠
摘要
Abstract
Objective To establish a model that integrates ultrasound features and immunological characteristics for predicting the efficacy of neoadjuvant chemotherapy(NAC)in breast cancer patients.Methods A total of 203 breast cancer patients undergoing preoperative NAC at the Fifth Medical Center of the PLA General Hospital between July 2021 and July 2024 were screened.In line with the inclusion/exclusion criteria,177 patients were included.Data on ultrasound and immunohistochemistry was collected.These patients were divided into pathological complete response(pCR)and non-pathological complete response(non-pCR)groups based on postoperative pathology.Factors with P＜0.0 1 in univariate analysis were evaluated using multivariate Logistic regression.Independent predictive factors were used to construct and validate the ultrasound-immunohistochemical model via Bootstrap.Results The reduction rateof the maximum diameter of lesions,posterior echo attenuation,PR status and HER-2 status were identified as independent predictors of pCR(all P＜0.05).The model proved to be highly accurate and stable.Conclusion The model that combines ultrasound and immunohistochemical features can effectively evaluatep CR after NAC in breast cancer patients.关键词
乳腺癌/新辅助化疗/病理完全缓解/超声特征/免疫组化/诺模图Key words
breast cancer/neoadjuvant chemotherapy/pathological complete response/ultrasound features/immunohis-tochemistry/nomogram分类
医药卫生引用本文复制引用
李兆云,庞月,陈翠京,毛京宁,杜芮,汉婉晴,田红丽,皋月娟,白玲..超声特征联合免疫组化建立乳腺癌新辅助化疗疗效的预测模型及价值分析[J].军事医学,2025,49(9):687-693,7.
